IVIG - West Nile Encephalitis: Safety and Efficacy
West Nile Virus
About this trial
This is an interventional treatment trial for West Nile Virus focused on measuring West Nile Virus, encephalitis, myelitis, immunoglobulin G
Eligibility Criteria
Inclusion Criteria: In order to participate in this clinical trial, all subjects (or legal representative) must provide written informed consent. Only patients meeting entry criteria will be enrolled. Eligible subjects must fall into one of two categories: A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis as defined below: New neurologic abnormality: Asymmetric extremity weakness without sensory abnormality; or Other neurologic abnormality (including altered level of consciousness, dysarthria and dysphagia) plus fever (subjective or objective) within the previous 4 days AND CSF examination within the previous 96 hours showing: Absence of organism on gram or fungal stain White blood cell count greater than or equal to 4 per cubic mm corrected for significant red blood cell contamination. Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose / plasma glucose greater than or equal to 0.4) Serum and CSF glucose levels should be obtained within 8 hours of each other for this calculation. OR B. Hospitalized patients, without encephalitis and/or myelitis as defined below, who meet the following criteria: A positive IgM serology or PCR test for WNV in blood or cerebrospinal fluid, AND Clinical illness compatible with WNV infection as described by occurrence of greater than or equal to 3 of the following findings during the preceding less than or equal to 10 days: Diarrhea Headache Fever > 38º C Nausea and/or vomiting Myalgias and/or arthralgias Nuchal rigidity Macular or papular rash New neurological abnormality AND A risk factor for the development of WNV neurologic disease as defined by: Age greater than or equal to 40 years, or Age greater than or equal to 18 years plus immunosuppression, as defined by any of the following: Hematologic malignancy; previous diagnosis of diabetes mellitus; chemotherapy within previous 4 weeks; stem cell transplant recipient or solid organ transplant recipient; taking immunosuppressive medications, including prednisone greater than or equal to 7.5 mg/day within the previous 4 weeks; history of human immunodeficiency virus (HIV) infection, congenital immunodeficiency syndrome (including common variable immunodeficiency) Exclusion Criteria: Unable to obtain valid informed consent History of intolerance (including anaphylaxis) to IVIg or related compounds Known history of IgA deficiency Known history of hypersensitivity to maltose History of (or at time of study entry) hyperviscosity syndrome, such as but not limited to: Waldenstrom's macroglobulinemia Multiple myeloma Total white blood cell count > 80,000/cubic mm Hematocrit > 55% Platelet count > 700,000/cubic mm Meets criteria of Class III or IV of the New York Heart Association Classification for congestive heart failure patients Serum creatinine > 2.5 mg/dL or requires dialysis Alternate explanation (as determined by the investigator) for clinical findings (such as structural brain lesion, cerebrovascular accident, or other infectious disease, including confirmed infections with other flaviviruses) Pregnant or breastfeeding (negative serum or urine pregnancy test within previous 72 hours if woman is not postmenopausal or has not been surgically sterilized) Investigator's opinion that patient would be unable to adhere to protocol requirements Receipt of ribavirin, interferon alpha, intravenous immunoglobulin, or any investigational drug for treatment of WNV or hepatitis within 15 days prior to study entry
Sites / Locations
- University of Alabama at Birmingham
- University of South Alabama Medical Center
- St. Joseph's Hospital and Medical Center
- Mayo Clinic Hospital
- University of Arizona Health Sciences Center
- University of Arkansas
- Enloe Medical Center
- Seton Medical Center
- City of Hope National Medical Center
- Kaiser Permanente South Bay Medical Center
- University of Southern California
- University of California Irvine
- University of California Davis Medical Center
- University of California San Francisco
- California Pacific Medical Center
- Santa Rosa Kaiser Medical
- Exempla St. Joseph Hospital
- University of Colorado
- George Washington University Medical Center
- Idaho Falls Infectious Diseases, PLLC
- Loyola University
- Indiana University
- University of Kansas Medical Center
- Via Christi Regional Medical Center
- University of Kentucky
- Tulane University
- Johns Hopkins University
- National Institutes of Health
- University of Michigan
- Wayne State University
- Washington University in St. Louis
- Saint Louis University
- Mercury Street Medical Group
- Infectious Disease Specialists, PC
- Central Nebraska Medical Clinic
- McCook Clinic, PC
- Great Plains Regional Medical Center
- VA Medical Center - Omaha
- Creighton University
- University of Nebraska Medical Center
- Clara Maass Medical Center
- University of New Mexico
- Flushing Hospital Medical Center
- St. Alexius Medical Center
- Dakota Clinic at Innovis
- MeritCare Hospital
- Trinity Health - Hospital
- University Hospital
- University Hospitals of Cleveland
- University of Toledo
- Wright-Patterson Medical Center
- Legacy Good Samaritan
- Lehigh Valley Hospital
- The Reading Hospital and Medical Center
- Memorial Hospital of RI
- Rhode Island Hospital
- Infectious Disease Consultations - Rapid City
- Avera Research Institute
- Vanderbilt University
- The University of Texas Southwestern Medical Center
- The University of Texas Medical Branch
- The University of Texas Health Science Center at Houston
- The University of Texas Health Science Center
- Wilford Hall Medical Center
- The University of Texas Health Science Center at Tyler
- University of Virginia
- University of Calgary
- University of Alberta
- University of Manitoba
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Active Comparator
Placebo Comparator
1
2
3
60 subjects to receive Omr-IgG-am.
20 subjects to receive Polygam® S/D (IVIG).
20 subjects to receive normal saline.